Travere Therapeutics (NASDAQ:TVTX) Insider Sells $101,417.10 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 2,174 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total value of $101,417.10. Following the completion of the transaction, the insider directly owned 107,287 shares of the company’s stock, valued at $5,004,938.55. This represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Down 0.1%

NASDAQ:TVTX opened at $42.60 on Friday. The firm’s 50 day simple moving average is $32.83 and its 200 day simple moving average is $32.94. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $48.61. The company has a market cap of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter last year, the firm earned ($0.47) earnings per share. The company’s revenue for the quarter was up 55.6% on a year-over-year basis. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TVTX. Vanguard Group Inc. boosted its position in shares of Travere Therapeutics by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock worth $158,059,000 after purchasing an additional 619,085 shares in the last quarter. State Street Corp grew its stake in shares of Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock valued at $181,752,000 after buying an additional 1,538,827 shares during the period. Perceptive Advisors LLC increased its position in Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after buying an additional 483,565 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in Travere Therapeutics by 27.4% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after buying an additional 599,102 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Travere Therapeutics by 28.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock worth $85,849,000 after buying an additional 494,665 shares during the period.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TVTX shares. Canaccord Genuity Group increased their price target on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Wells Fargo & Company lifted their price objective on Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday. Guggenheim upped their target price on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. Citigroup increased their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.